A phase III trial of Bevacizumab biosimilar RPH-001 for colorectal cancer.
Latest Information Update: 25 Jul 2017
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 25 Jul 2017 New trial record